| Project/Area Number |
13670183
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Fukushima Medical University School of Medicine |
|---|
Principal Investigator |
NAKAMURA Naoya School of Medicine Assist. Professor, 医学部, 講師 (50227922)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TASAKI Kazuhiro School of Medicine Instructor, 医学部, 助手 (70244382)
ONO Nobutaka School of Medicine Instructor, 医学部, 助手 (80233584)
|
|---|
| Project Period (FY) |
2001 – 2002
|
| Project Status |
Completed (Fiscal Year 2002)
|
| Budget Amount *help |
¥2,600,000 (Direct Cost: ¥2,600,000)
Fiscal Year 2002: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2001: ¥1,500,000 (Direct Cost: ¥1,500,000)
|
|---|
| Keywords | Diffuse large B-cell lymphoma / CD5 / immunoglobulin / Somatic mutation / bcl-6 / immunohistochemistry / Microarray / immunoglobulin heavy chain gene / bcl-6 gene / DNA microarray / CD27 |
|---|
| Research Abstract |
We studied clinicopathologic, Immunologic and molecular characteristics of CD5-positve (^+) diffuse large B-cell lymphoma (DLBCL) and compared CD5^+ DLBCL to CD5^- DLBCL. CD5^- DLBCLs are identified a subgroup which represents elderly onset, female predominance, frequent involvement of extranodal sites and a poor clinical course. Somatic mutation frequency and pattern of the rearranged immunoglobulin heavy chain gene variable region (VH) gene indicated that 35 cases of CD5+ DLBCLs were divided into 13 cases with germline or low frequency mutation (<5%) ; low group and 22 cases with somatically hypermutated VH gene (>5%) ; high group. Somatic mutation of bcl-6 gene promoter region was found in five cases with one nucleotide substitution and six cases with germline. Low group included a case with nucleotide substitution and a case with germline, and high group included three cases with nucleotide substitution and three cases with germline. No cases in low group expressed CD27, CD38 or CD147 except CD38 in one and CD148 in one, but some cases in high group expressed these molecules. The pattern of expression of some genes in DNA microarray was different CD5^+ DLBCL and CD5^- DLBCL. Thus, we found some differences between CD5^+ DLBCL and CD5^- DLBCL, and concluded CD5^+ DLBCL was a distinct subgroup of DLBCL. A new therapy other than conventional chemotherapy is needed for the patients with CD5^+ DLBCL.
|
